Williams Jennet, Short Dee, Dayal Linda, Strickland Sarah, Harvey Richard, Tin Terry, Savage Philip M, Seckl Michael J
J Reprod Med. 2014 May-Jun;59(5-6):248-54.
To examine the effects of early pregnancy (< 12 months following chemotherapy) on a recent cohort of women treated with modern therapies for gestational trophoblastic neoplasia (GTN).
The Charing Cross GTN database was screened between 1998-2012 to identify 1,204 patients treated with either single-agent (61.9%) or multiagent (38.1%) chemotherapy.
A total of 23% of single-agent and 15.4% of the multiagent treatment groups conceived within 12 months of chemotherapy, resulting in 255 early pregnancies, with 73.3% resulting in live births. There was no significant increased risk of miscarriage, ectopic pregnancy, second molar pregnancy or stillbirth as compared to the general U.K. population. Intriguingly, the incidence of relapse was only 1.7% in the early pregnancy group as compared to 5.2% in the 963 patients who did not conceive early.
Women who become pregnant within 12 months postchemotherapy for GTN can be reassured of a likely favorable outcome, although the safest option is still to delay pregnancy for a year.
研究早期妊娠（化疗后<12个月）对近期接受现代疗法治疗妊娠滋养细胞肿瘤（GTN）的一组女性的影响。
对1998年至2012年间的查令十字GTN数据库进行筛选，以确定1204例接受单药（61.9%）或多药（38.1%）化疗的患者。
单药治疗组共有23%的患者以及多药治疗组15.4%的患者在化疗后12个月内怀孕，共255例早期妊娠，其中73.3%为活产。与英国普通人群相比，流产、宫外孕、妊娠滋养细胞肿瘤妊娠或死产的风险没有显著增加。有趣的是，早期妊娠组的复发率仅为1.7%，而未早期怀孕的963例患者的复发率为5.2%。
化疗后12个月内怀孕的GTN女性可以放心，可能会有良好的结局，尽管最安全的选择仍然是将怀孕推迟一年。
